Pill Identifier App

Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'

NEW BRUNSWICK, N.J., October 20, 2008 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting her findings related to Senesco's preclinical multiple myeloma data at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." Ms. Taylor is a member of the Department of Biology at the University of Waterloo, Ontario, Canada. The conference will take place from October 21-24 in Geneva, Switzerland.

 

Senesco's President and CEO, Bruce Galton, Executive Vice President and CSO, Dr. John E. Thompson, and Vice President of R&D, Richard Dondero, are all co-authors of the study entitled "Therapeutic intervention in a murine model of multiple myeloma with PEI nanocomplexes bearing an eIF5A siRNA and eIF5AK50R pDNA resulted in a significant anti-tumoural response."

 

A copy of the poster will be available at www.senesco.com once the presentation has been made.

 

 

 

 

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

 

 

 

 

    Company Contacts:                           Investor Relations Contact:
    Senesco Technologies, Inc.                  FD
    Bruce Galton                                Brian Ritchie
    Chief Executive Officer                     (brian.ritchie@fd.com)
    (bgalton@senesco.com)                       (212) 850-5600
    (732) 296-8400
     

CONTACT: Company, Bruce Galton, Chief Executive Officer, SenescoTechnologies, Inc., +1-732-296-8400, , or Investors,Brian Ritchie, FD, +1-212-850-5600, bgalton@senesco.com brian.ritchie@fd.com

Web site: http://www.senesco.com/

Ticker Symbol: (NYSE:SNT),(NYSE:SNT)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2008

View comments

Hide
(web2)